Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-09-15 17:03:13 ET · period of report 2026-09-11 · accession 0001909817-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-15 17:03 | 2026-09-11 | NBIX | Boyer David W. | Chief Corp. Affairs Off | A - Grant | $0.00 | +3,587 | 11.5K | +45% | $0 |
| T | 2026-09-15 17:03 | 2026-09-11 | NBIX | Boyer David W. | Chief Corp. Affairs Off | F - Tax | $156.22 | -1,936 | 9,548 | -17% | -$302.4K |
| T | 2026-09-15 17:03 | 2026-09-14 | NBIX | Boyer David W. | Chief Corp. Affairs Off | S - Sale | $157.45 | -826 | 8,722 | -9% | -$130.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-11 | A | A | 3,587 | $0.00 | 11,484 | D | — | — | (F1) The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. (F2) Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2026-09-11 | F | D | 1,936 | $156.22 | 9,548 | D | — | — | (F3) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
| 3 | Common | Common Stock | 2026-09-14 | S | D | 826 | $157.45 | 8,722 | D | — | — | (F4) The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F5) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |